AlphaRx ins Depot nehmen ??? - 500 Beiträge pro Seite
eröffnet am 29.01.08 12:54:55 von
neuester Beitrag 19.09.08 11:35:43 von
neuester Beitrag 19.09.08 11:35:43 von
Beiträge: 6
ID: 1.137.884
ID: 1.137.884
Aufrufe heute: 0
Gesamt: 2.039
Gesamt: 2.039
Aktive User: 0
ISIN: US02081D2080 · WKN: A0B8ZD
Neuigkeiten
Werte aus der Branche Finanzdienstleistungen
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,9000 | +20,00 | |
| 2,1875 | +19,37 | |
| 4,5000 | +15,38 | |
| 6,3000 | +14,55 | |
| 0,5700 | +14,00 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,3500 | -10,60 | |
| 7,16 | -12,04 | |
| 12,90 | -20,07 | |
| 1,5000 | -23,08 | |
| 1,5000 | -40,00 |
Feedback
29.01.2008 - 10:20 Uhr
AlphaRx ins Depot nehmen
Endingen (aktiencheck.de AG) - Die Experten von "Global Insider Investing" raten eine Startposition der AlphaRx-Aktie (ISIN US02081D2080/ WKN A0B8ZD) ins Depot zu nehmen.
Die AlphaRx-Aktie sei von USD 0,05 bis auf USD 0,26 gestiegen und sei seit Jahresbeginn auf USD 0,14 zurückgefallen. Würde man die Insidersignale richtig deuten, so dürften diese Rücksetzer nur eine kurze Verschnaufpause vor dem erneuten Angriff auf die Rekordhochs darstellen. Michael Lee, Gründer und CEO von AlphaRx, habe am 15. Januar erneut 520.000 Stücke für USD 0,16 gekauft, nachdem er schon im November und Dezember 1,5 Mio. Aktien erworben habe. Außerdem hätten neben Lee drei weitere Vorstandsmitglieder Aktienoptionen im Wert von USD 415.000 ausgeübt.
Die Experten von "Global Insider Investing" raten eine Startposition der AlphaRx-Aktie ins Depot zu nehmen und diese mit einem großzügigen Stopp-Loss abzusichern. (Ausgabe 02 vom 28.01.2008) (29.01.2008/ac/a/a) Analyse-Datum: 29.01.2008
Quelle: Finanzen.net
AlphaRx ins Depot nehmen
Endingen (aktiencheck.de AG) - Die Experten von "Global Insider Investing" raten eine Startposition der AlphaRx-Aktie (ISIN US02081D2080/ WKN A0B8ZD) ins Depot zu nehmen.
Die AlphaRx-Aktie sei von USD 0,05 bis auf USD 0,26 gestiegen und sei seit Jahresbeginn auf USD 0,14 zurückgefallen. Würde man die Insidersignale richtig deuten, so dürften diese Rücksetzer nur eine kurze Verschnaufpause vor dem erneuten Angriff auf die Rekordhochs darstellen. Michael Lee, Gründer und CEO von AlphaRx, habe am 15. Januar erneut 520.000 Stücke für USD 0,16 gekauft, nachdem er schon im November und Dezember 1,5 Mio. Aktien erworben habe. Außerdem hätten neben Lee drei weitere Vorstandsmitglieder Aktienoptionen im Wert von USD 415.000 ausgeübt.
Die Experten von "Global Insider Investing" raten eine Startposition der AlphaRx-Aktie ins Depot zu nehmen und diese mit einem großzügigen Stopp-Loss abzusichern. (Ausgabe 02 vom 28.01.2008) (29.01.2008/ac/a/a) Analyse-Datum: 29.01.2008
Quelle: Finanzen.net
AlphaRx Initiates Indaflex(TM) China Registration
Tuesday January 29, 8:00 am ET
MARKHAM, ON, Jan. 29 /PRNewswire-FirstCall/ - AlphaRx (OTC BB:ALRX - News), an emerging biopharmaceutical company utilizing proprietary drug delivery technology to develop novel formulations of drugs, is pleased to announce that it has commenced preparation of the dossier for the registration of Indaflex(TM) in China.
Indaflex(TM) is a topical NSAID (Non-Steroidal Anti-Inflammatory Drug) formulation in clinical development for the reduction of signs and symptoms associated with osteoarthritis of the knee. The Company expects to file a New Drug Application to the China State Food & Drug Administration (SFDA) in April 2008. The application will be placed under Class 3.1 and as such, the Company is allowed to set Indaflex(TM)'s retail price. This is significant as drug prices are under Government control in China.
The Company will be required to conduct a confirmatory human trial with 240 patients in 2 arms over a 4 weeks treatment period. The Company anticipates completing this trial by Q4 of 2008 in Beijing and Shanghai. Subject to the successful completion of this confirmatory trial, approval from the SFDA of Indaflex(TM) should be received in Q4 of 2009. Upon approval, this will allow for initiation of a comprehensive marketing and distribution campaign.
About AlphaRx Inc.
AlphaRx is a specialty pharmaceutical company utilizing proprietary site-specific nanoparticulate drug delivery systems to develop novel formulations of drugs that are insoluble or poorly soluble in water or have yet to be administrable to the human body with an acceptable delivery method. The Company's product candidates address various pharmaceutical markets, including inflammation, tuberculosis and pneumonia.
Forward Looking Statements:
This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the companies.
Copyright @ 2008. AlphaRx Inc.
------------------------------
Source: AlphaRx Inc.
http://biz.yahoo.com/prnews/080129/to441.html?.v=31&printer=…
Tuesday January 29, 8:00 am ET
MARKHAM, ON, Jan. 29 /PRNewswire-FirstCall/ - AlphaRx (OTC BB:ALRX - News), an emerging biopharmaceutical company utilizing proprietary drug delivery technology to develop novel formulations of drugs, is pleased to announce that it has commenced preparation of the dossier for the registration of Indaflex(TM) in China.
Indaflex(TM) is a topical NSAID (Non-Steroidal Anti-Inflammatory Drug) formulation in clinical development for the reduction of signs and symptoms associated with osteoarthritis of the knee. The Company expects to file a New Drug Application to the China State Food & Drug Administration (SFDA) in April 2008. The application will be placed under Class 3.1 and as such, the Company is allowed to set Indaflex(TM)'s retail price. This is significant as drug prices are under Government control in China.
The Company will be required to conduct a confirmatory human trial with 240 patients in 2 arms over a 4 weeks treatment period. The Company anticipates completing this trial by Q4 of 2008 in Beijing and Shanghai. Subject to the successful completion of this confirmatory trial, approval from the SFDA of Indaflex(TM) should be received in Q4 of 2009. Upon approval, this will allow for initiation of a comprehensive marketing and distribution campaign.
About AlphaRx Inc.
AlphaRx is a specialty pharmaceutical company utilizing proprietary site-specific nanoparticulate drug delivery systems to develop novel formulations of drugs that are insoluble or poorly soluble in water or have yet to be administrable to the human body with an acceptable delivery method. The Company's product candidates address various pharmaceutical markets, including inflammation, tuberculosis and pneumonia.
Forward Looking Statements:
This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the companies.
Copyright @ 2008. AlphaRx Inc.
------------------------------
Source: AlphaRx Inc.
http://biz.yahoo.com/prnews/080129/to441.html?.v=31&printer=…
AlphaRx Announces Non-Brokered Private Placement
Tuesday March 25, 8:00 am ET
MARKHAM, ON, March 25 /PRNewswire-FirstCall/ - AlphaRx (OTC BB:ALRX - News), is pleased to announce a proposed non-brokered private placement in conjunction with its proposed TSX Venture Exchange listing application, subject to TSX Venture Exchange approval, of 16,000,000 units at a price of US$0.10 per unit, for gross proceeds of US$1,600,000.
Each unit consists of one common share plus one-half common share purchase warrant. Each whole common share purchase warrant will enable the holder to purchase one common share at a price of $0.125 for a period of 24 months from closing. Closing of the private placement is subject to the Company's common shares being listed and posted for trading on the TSX Venture Exchange and the Company becomes a "qualifying issuer" as such term is defined in Multi-Lateral Instrument 45-102 of the Canadian Securities Administrators ("MI 45-102") resulting in the securities issued in the private placement qualifying for a four month hold period pursuant to MI 45-102.
The TSX Venture Exchange has not reviewed this news release and does not
accept responsibility for the adequacy or accuracy of this news release.
The TSXV has neither approved nor disapproved the contents of this news
release.
About AlphaRx Inc.
AlphaRx is a specialty pharmaceutical company utilizing proprietary site-specific nanoparticulate drug delivery systems to develop novel formulations of drugs that are insoluble or poorly soluble in water or have yet to be administrable to the human body with an acceptable delivery method. The Company's product candidates address various pharmaceutical markets, including inflammation, tuberculosis and pneumonia.
Forward Looking Statements:
This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the companies.
Copyright @ 2008. AlphaRx Inc.
http://biz.yahoo.com/prnews/080325/to399.html?.v=37
Tuesday March 25, 8:00 am ET
MARKHAM, ON, March 25 /PRNewswire-FirstCall/ - AlphaRx (OTC BB:ALRX - News), is pleased to announce a proposed non-brokered private placement in conjunction with its proposed TSX Venture Exchange listing application, subject to TSX Venture Exchange approval, of 16,000,000 units at a price of US$0.10 per unit, for gross proceeds of US$1,600,000.
Each unit consists of one common share plus one-half common share purchase warrant. Each whole common share purchase warrant will enable the holder to purchase one common share at a price of $0.125 for a period of 24 months from closing. Closing of the private placement is subject to the Company's common shares being listed and posted for trading on the TSX Venture Exchange and the Company becomes a "qualifying issuer" as such term is defined in Multi-Lateral Instrument 45-102 of the Canadian Securities Administrators ("MI 45-102") resulting in the securities issued in the private placement qualifying for a four month hold period pursuant to MI 45-102.
The TSX Venture Exchange has not reviewed this news release and does not
accept responsibility for the adequacy or accuracy of this news release.
The TSXV has neither approved nor disapproved the contents of this news
release.
About AlphaRx Inc.
AlphaRx is a specialty pharmaceutical company utilizing proprietary site-specific nanoparticulate drug delivery systems to develop novel formulations of drugs that are insoluble or poorly soluble in water or have yet to be administrable to the human body with an acceptable delivery method. The Company's product candidates address various pharmaceutical markets, including inflammation, tuberculosis and pneumonia.
Forward Looking Statements:
This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the companies.
Copyright @ 2008. AlphaRx Inc.
http://biz.yahoo.com/prnews/080325/to399.html?.v=37
Zysolin Shows Promising Results in Animal Study
Tuesday June 3, 8:00 am ET
AlphaRx's specially-formulated Tobramycin nanoparticles increase survival rate in mice infected with Gram negative Pseudomonas Aeruginosa, suggesting Zysolin has potential in the treatment of Cystic Fibrosis and Gram-negative pneumonia.
MARKHAM, ON, June 3 /PRNewswire-FirstCall/ - AlphaRx (OTC BB:ALRX - News) is pleased to announce pre-clinical data on Zysolin(TM), a Tobramycin compound encapsulated in the company's Nano Drug Delivery Platform intended for the treatment of Cystic Fibrosis and an adjunctive treatment of Gram-negative pneumonia in intubated and mechanically-ventilated patients.
In the recent animal study, the therapeutic efficacy of Zysolin was investigated in a mouse model of Pseudomonas aeruginosa pneumonia. In this acute model, pneumonia developed rapidly, resulting in a high mortality rate, no mice survived after 24 hours of infection without treatment. Mice treated with Zysolin(TM) showed significantly better efficacy than Tobramycin, achieving 60% survival rate vs. 40% in the Tobramycin treatment group. An increase of survival by 50% or more, relative to vehicle control, indicates significant anti-microbial effect. The Tobramycin treatment group did not meet the study's end point.
Pseudomonas aeruginosa is a major cause of lung infections, particularly nosocomial pneumonia. Mortality rates of patients with P. aeruginosa pneumonia are higher than the mortality rates of patients with pneumonia caused by other pathogens because P. aeruginosa pneumonia frequently disseminates to cause bacteremia and sepsis. Currently, Gram-negative pneumonia carries a mortality risk as high as 50 percent in mechanically-ventilated patients.
About AlphaRx Inc.
AlphaRx is a specialty pharmaceutical company utilizing proprietary site-specific nanoparticulate drug delivery systems to develop novel formulations of drugs that are insoluble or poorly soluble in water or have yet to be administrable to the human body with an acceptable delivery method.
http://biz.yahoo.com/prnews/080603/to238.html?.v=72&printer=…
Tuesday June 3, 8:00 am ET
AlphaRx's specially-formulated Tobramycin nanoparticles increase survival rate in mice infected with Gram negative Pseudomonas Aeruginosa, suggesting Zysolin has potential in the treatment of Cystic Fibrosis and Gram-negative pneumonia.
MARKHAM, ON, June 3 /PRNewswire-FirstCall/ - AlphaRx (OTC BB:ALRX - News) is pleased to announce pre-clinical data on Zysolin(TM), a Tobramycin compound encapsulated in the company's Nano Drug Delivery Platform intended for the treatment of Cystic Fibrosis and an adjunctive treatment of Gram-negative pneumonia in intubated and mechanically-ventilated patients.
In the recent animal study, the therapeutic efficacy of Zysolin was investigated in a mouse model of Pseudomonas aeruginosa pneumonia. In this acute model, pneumonia developed rapidly, resulting in a high mortality rate, no mice survived after 24 hours of infection without treatment. Mice treated with Zysolin(TM) showed significantly better efficacy than Tobramycin, achieving 60% survival rate vs. 40% in the Tobramycin treatment group. An increase of survival by 50% or more, relative to vehicle control, indicates significant anti-microbial effect. The Tobramycin treatment group did not meet the study's end point.
Pseudomonas aeruginosa is a major cause of lung infections, particularly nosocomial pneumonia. Mortality rates of patients with P. aeruginosa pneumonia are higher than the mortality rates of patients with pneumonia caused by other pathogens because P. aeruginosa pneumonia frequently disseminates to cause bacteremia and sepsis. Currently, Gram-negative pneumonia carries a mortality risk as high as 50 percent in mechanically-ventilated patients.
About AlphaRx Inc.
AlphaRx is a specialty pharmaceutical company utilizing proprietary site-specific nanoparticulate drug delivery systems to develop novel formulations of drugs that are insoluble or poorly soluble in water or have yet to be administrable to the human body with an acceptable delivery method.
http://biz.yahoo.com/prnews/080603/to238.html?.v=72&printer=…
AlphaRx Receives Conditional Approval to List on the TSX Venture Exchange
http://biz.yahoo.com/prnews/080812/to775.html?.v=1
http://biz.yahoo.com/prnews/080812/to775.html?.v=1
Trading Spotlight
AlphaRx Appoints Leading Infectious Disease Specialist to Its Scientific Advisory Board
Wednesday September 17, 8:00 am ET
MARKHAM, ON, Sept. 17 /PRNewswire-FirstCall/ - AlphaRx Inc. (OTCBB: ALRX - News) is pleased to announce the appointment of Dr. Donald Low to its Scientific Advisory Board (SAB), effective immediately. With more than 30 years of experience, Dr. Low is recognized world-wide as an authority in the area of emerging infectious diseases.
http://biz.yahoo.com/prnews/080917/to797.html?.v=2
Wednesday September 17, 8:00 am ET
MARKHAM, ON, Sept. 17 /PRNewswire-FirstCall/ - AlphaRx Inc. (OTCBB: ALRX - News) is pleased to announce the appointment of Dr. Donald Low to its Scientific Advisory Board (SAB), effective immediately. With more than 30 years of experience, Dr. Low is recognized world-wide as an authority in the area of emerging infectious diseases.
http://biz.yahoo.com/prnews/080917/to797.html?.v=2
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| -1,48 | |
| +0,62 | |
| -99,00 | |
| +1,85 | |
| -1,07 | |
| 0,00 | |
| +1,13 | |
| 0,00 | |
| 0,00 | |
| +2,34 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 217 | ||
| 90 | ||
| 77 | ||
| 60 | ||
| 50 | ||
| 36 | ||
| 34 | ||
| 31 | ||
| 27 | ||
| 25 |
